Author's Reply to: "Comment on: Pharmacokinetics and Safety of Recombinant Human Interleukin-1 Receptor Antagonist GR007 in Chinese Healthy Subjects".
作者信息
Xie Ran, Zhang Yang, Zhao Nan, Zhou Shuang, Wang Xin, Han Wei, Yu Yan, Zhao Xia, Cui Yimin
机构信息
Department of Pharmacy, Peking University First Hospital, Beijing, 100034, People's Republic of China.
Shanghai Municipality Key Laboratory of Veterinary Biotechnology, School of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
出版信息
Eur J Drug Metab Pharmacokinet. 2019 Oct;44(5):723-724. doi: 10.1007/s13318-019-00574-8.
Abstract
摘要
相似文献
1
Author's Reply to: "Comment on: Pharmacokinetics and Safety of Recombinant Human Interleukin-1 Receptor Antagonist GR007 in Chinese Healthy Subjects".
Eur J Drug Metab Pharmacokinet. 2019 Oct;44(5):723-724. doi: 10.1007/s13318-019-00574-8.
2
Pharmacokinetics and Safety of Recombinant Human Interleukin-1 Receptor Antagonist GR007 in Healthy Chinese Subjects.
Eur J Drug Metab Pharmacokinet. 2019 Jun;44(3):353-360. doi: 10.1007/s13318-018-0523-5.
3
Comment on: Pharmacokinetics and Safety of Recombinant Human Interleukin-1 Receptor Antagonist GR007 in Healthy Chinese Subjects.
Eur J Drug Metab Pharmacokinet. 2019 Oct;44(5):719-721. doi: 10.1007/s13318-019-00566-8.
4
Author's Reply to Srinivas: "A Single Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Orally Administered Des-Aspartate Angiotensin I in Healthy Subjects".
Drugs R D. 2017 Mar;17(1):243-244. doi: 10.1007/s40268-016-0156-6.
5
Pharmacodynamics of subcutaneous recombinant human interleukin-10 in healthy volunteers.
Clin Pharmacol Ther. 1997 Aug;62(2):171-80. doi: 10.1016/S0009-9236(97)90065-5.
6
Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis.
J Rheumatol. 2004 Oct;31(10):2071-5.
7
Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.
Clin Pharmacokinet. 2016 Aug;55(8):943-55. doi: 10.1007/s40262-016-0366-7.
8
Crystals of soluble interleukin-1 receptor complexed with its natural antagonist reveal a 1:1 receptor-ligand complex.
FEBS Lett. 1995 Oct 2;373(1):39-40. doi: 10.1016/0014-5793(95)01009-4.
9
Dermal interleukin-1 expression and effective and long-lasting therapy with interleukin-1 receptor antagonist anakinra in Schnitzler syndrome.
Acta Derm Venereol. 2012 Jul;92(4):393-4. doi: 10.2340/00015555-1307.
10
Alternative views on the effects of recombinant interleukin-1-receptor antagonist.
Am J Hosp Pharm. 1994 Nov 1;51(21):2724-7.
本文引用的文献
1
Comment on: Pharmacokinetics and Safety of Recombinant Human Interleukin-1 Receptor Antagonist GR007 in Healthy Chinese Subjects.
Eur J Drug Metab Pharmacokinet. 2019 Oct;44(5):719-721. doi: 10.1007/s13318-019-00566-8.
2
Intramuscular and intravenous levetiracetam in humans: safety and pharmacokinetics.
Epilepsy Res. 2010 Oct;91(2-3):289-92. doi: 10.1016/j.eplepsyres.2010.07.016. Epub 2010 Aug 14.
3
Establishing best practice guidelines for administration of intra muscular injections in the adult: a systematic review of the literature.
Contemp Nurse. 2005 Dec;20(2):267-77. doi: 10.5172/conu.20.2.267.
Zotero 插件